GlassScriptPhysician profile
Amanda P Shukla
NPI 1346629227
$3,046.65
in general payments reported to CMS, 2019-2025
25 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.15 · 2020: $14.51 · 2021: $569 · 2022: $14.85 · 2023: $98.62 · 2024: $492 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.17 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.10 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $417.83 | 2021-2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.87 | 2025 | Caplyta |
| Abbvie INC. | $171.16 | 2021-2025 | |
| Stryker Corporation | $166.54 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $164.51 | 2020-2024 | Xarelto |
| Corcept Therapeutics | $157.52 | 2025 | Korlym |
| Ardelyx, INC. | $141.62 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $124.75 | 2025 | Voquezna |
| Amarin Pharma, INC. | $116.32 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $98.62 | 2023 | Inpefa |
| Janssen Biotech, INC. | $84.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $71.76 | 2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $62.85 | 2021 | |
| Arbor Pharmaceuticals, INC. | $60.78 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $53.17 | 2021 | |
| Exact Sciences Corporation | $51.29 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $45.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.86 | 2019 | |
| Pfizer INC. | $24.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $24.90 | 2021 | |
| Lundbeck LLC | $19.80 | 2025 | Rexulti |
| Biofrontera INC. | $14.85 | 2022 | |
| Novo Nordisk INC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.